You are here: Industry Insights > izencitinib

News List

Theravance Biopharma, Inc. Announces Top-line Results from Phase 2b Dose-Finding Induction Study of Izencitinib in Patients with Ulcerative Colitis drugs
August 24, 2021
Theravance Biopharma, Inc. today announced top-line results from its Phase 2b dose-finding induction study of izencitinib, an orally administered, gut-selective pan-Janus kinase (JAK) inhibitor in development for the treatment of ulcerative colitis.
J&J, Theravance's izencitinib fails Phase II ulcerative colitis trial firstwordpharma
August 24, 2021
Shares in Theravance Biopharma tumbled about 22% in after-hours trade on Monday after the company said izencitinib did not meet the primary endpoint of a Phase IIb trial of patients with ulcerative colitis (UC).
Theravance Biopharma Announces Proposed Public Offering of Ordinary Shares firstwordpharma
June 25, 2021
Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma"), announced today that it intends to offer its ordinary shares in an underwritten public offering.
Theravance Biopharma Plans Upcoming Stock Sale; Shares Sink Nearly 10% in Extended Trading firstwordpharma
June 25, 2021
Shares of Theravance Biopharma were down almost 10% in after-hours trading on Thursday after the company disclosed plans for a public offering of its common stock, as reported by Fidelity.